Pivekimab, also IBAT®, constitutes a novel genetically engineered targeted antibody designed to selectively interact with and inhibit IL-6, a critical molecule implicated in various inflammatory mechanisms contributing

The increasing field of immuno-oncology is centered on exploiting the immune system's own defenses against tumors. Concerning these strategies, inhibiting MAGEA3 with engineered antibodies holds considerable promise. MAGEA3, a member of the melanoma-associated antigen family, is frequently overex